APA (7th ed.) Citation

Li, J., Yue, H., Li, W., Zhu, G., Zhu, T., Chen, R., & Lu, X. (2021). Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. BMC.

Chicago Style (17th ed.) Citation

Li, Jun, Huiran Yue, Wenzhi Li, Guohua Zhu, Tingting Zhu, Ruifang Chen, and Xin Lu. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.

MLA (8th ed.) Citation

Li, Jun, et al. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.